Utah Medical Products
This article was originally published in The Gray Sheet
Trading of the firm's stock on the Nasdaq composite under the new symbol UTMD begins March 8. Currently listed on the New York Stock Exchange, the firm is making the switch because of its inability to reach the NYSE's $50 mil. shareholders' equity threshold, the company explains
You may also be interested in...
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.